...
首页> 外文期刊>Viruses >Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17?¢????36
【24h】

Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17?¢????36

机译:抗体竞争揭示了HPV L2次要衣壳蛋白残基的表面位置17 ???????? 36

获取原文
           

摘要

The currently available nonavalent human papillomavirus (HPV) vaccine exploits the highly antigenic L1 major capsid protein to promote high-titer neutralizing antibodies, but is limited to the HPV types included in the vaccine since the responses are highly type-specific. The limited cross-protection offered by the L1 virus-like particle (VLP) vaccine warrants further investigation into cross-protective L2 epitopes. The L2 proteins are yet to be fully characterized as to their precise placement in the virion. Adding to the difficulties in localizing L2, studies have suggested that L2 epitopes are not well exposed on the surface of the mature capsid prior to cellular engagement. Using a series of competition assays between previously mapped anti-L1 monoclonal antibodies (mAbs) (H16.V5, H16.U4 and H16.7E) and novel anti-L2 mAbs, we probed the capsid surface for the location of an L2 epitope (aa17?¢????36). The previously characterized L1 epitopes together with our competition data is consistent with a proposed L2 epitope within the canyons of pentavalent capsomers.
机译:当前可用的非价人类乳头瘤病毒(HPV)疫苗利用高度抗原化的L1主要衣壳蛋白来促进高滴度中和抗体,但由于该应答具有高度的类型特异性,因此仅限于疫苗中包含的HPV类型。 L1病毒样颗粒(VLP)疫苗提供的有限交叉保护值得进一步研究交叉保护性L2表位。 L2蛋白在病毒粒子中的精确位置尚未完全表征。除了定位L2的困难外,研究还表明,在细胞参与之前,L2表位在成熟衣壳表面的暴露程度不高。通过在先前定位的抗L1单克隆抗体(mAb)(H16.V5,H16.U4和H16.7E)与新型抗L2 mAb之间进行一系列竞争分析,我们检测了衣壳表面L2表位的位置( aa17?¢ ???? 36)。先前表征的L1表位以及我们的竞争数据与五价Capsomer峡谷内提议的L2表位一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号